ArticleFertility and sterility2016
Is FMR1 CGG repeat length a predictor of in vitro fertilization stimulation response or outcome?
Article in Fertility and sterility, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Does theFMR1 gene affect IVF success?Reproductive biomedicine online · 2019Pooled it
- Article
- The association of CGG repeat length and AGG interruption patterns on FMR1 alleles with female infertility.Frontiers in endocrinology · 2025Article
- Mortality in Women across theCells · 2023Article
- Mechanisms of ovarian aging.Reproduction (Cambridge, England) · 2021Review
- The molecular mechanisms that underlie fragile X-associated premature ovarian insufficiency: is it RNA or protein based?Molecular human reproduction · 2020Review
- FMR1 expression in human granulosa cells increases with exon 1 CGG repeat length depending on ovarian reserve.Reproductive biology and endocrinology : RB&E · 2018Article
- Article
- The importance of redundancy of functional ovarian reserve when investigating potential genetic effects on ovarian function.Journal of assisted reproduction and genetics · 2016Article
- Low normal FMR1 genotype in older adult women: Psychological well-being and motor function.Archives of gerontology and geriatricsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveTo study a broad range of FMR1 CGG repeat lengths and assisted reproduction technology (ART) outcomes.
designRetrospective cohort study.
settingPrivate ART practice. PATIENT(S): Fresh autologous ART stimulation cycles. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Oocyte yield, live birth. RESULT(S): We screened 14,088 fresh autologous ART cycles from 2012 to 2015, of which 4,690 cycles in 3,290 patients met the inclusion criteria. The FMR1 repeat length was statistically significantly but weakly associated with oocyte yield and other markers of ovarian response. The receiver operating characteristic curve analysis suggested extremely limited predictive ability. Moreover, the FMR1 repeat length was not statistically significantly associated with outcomes in multivariable models, including other markers of ovarian reserve. The FMR1 repeat length was not associated with embryo quality or live birth. Only patient age had a strong ability to predict live birth. CONCLUSION(S): The FMR1 repeat length is associated with ART response, but only weakly. It provides no incremental predictive ability beyond the conventionally used predictors, including patient age, antimüllerian hormone concentration, antral follicle count, and follicle-stimulating hormone level. These data suggest a possible role of the FMR1 repeat length within the normal range in ovarian response but demonstrate no clinically relevant indication for testing FMR1 as a predictor of ART outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.